JP2016528217A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528217A5 JP2016528217A5 JP2016529868A JP2016529868A JP2016528217A5 JP 2016528217 A5 JP2016528217 A5 JP 2016528217A5 JP 2016529868 A JP2016529868 A JP 2016529868A JP 2016529868 A JP2016529868 A JP 2016529868A JP 2016528217 A5 JP2016528217 A5 JP 2016528217A5
- Authority
- JP
- Japan
- Prior art keywords
- chemotherapeutic agent
- nucleoside analog
- combination
- taxane
- activated prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010021143 Hypoxia Diseases 0.000 claims 10
- 230000007954 hypoxia Effects 0.000 claims 10
- 229940002612 prodrug Drugs 0.000 claims 10
- 239000000651 prodrug Substances 0.000 claims 10
- 229940123237 Taxane Drugs 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 9
- 229940127089 cytotoxic agent Drugs 0.000 claims 9
- 239000002777 nucleoside Substances 0.000 claims 9
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 7
- 229960001592 paclitaxel Drugs 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361859152P | 2013-07-26 | 2013-07-26 | |
| US61/859,152 | 2013-07-26 | ||
| US201361887873P | 2013-10-07 | 2013-10-07 | |
| US61/887,873 | 2013-10-07 | ||
| US201461994295P | 2014-05-16 | 2014-05-16 | |
| US61/994,295 | 2014-05-16 | ||
| PCT/US2014/047885 WO2015013448A1 (en) | 2013-07-26 | 2014-07-23 | Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016528217A JP2016528217A (ja) | 2016-09-15 |
| JP2016528217A5 true JP2016528217A5 (https=) | 2017-08-31 |
Family
ID=51299053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529868A Pending JP2016528217A (ja) | 2013-07-26 | 2014-07-23 | 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160158253A1 (https=) |
| EP (1) | EP3024490A1 (https=) |
| JP (1) | JP2016528217A (https=) |
| CN (1) | CN105792845A (https=) |
| WO (1) | WO2015013448A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017192863A1 (en) * | 2016-05-04 | 2017-11-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| CN106279321A (zh) | 2016-08-09 | 2017-01-04 | 南京医科大学 | 吉西他滨ProTide乏氧活化前药及其应用 |
| CN110168658B (zh) * | 2016-10-05 | 2024-04-02 | 皇家飞利浦有限公司 | 患者监测系统和方法 |
| CN112533541A (zh) * | 2018-03-23 | 2021-03-19 | 阿德诺西特有限责任公司 | 诱导细胞和/或组织片段片状剥脱以增强细胞病理性细胞收集的方法 |
| CN110680824A (zh) * | 2018-07-05 | 2020-01-14 | 深圳艾欣达伟医药科技有限公司 | 埃夫索胺的抗癌医药用途 |
| CN117651548B (zh) | 2021-08-27 | 2026-03-03 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| WO2023025312A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 使用th-302治疗parp抑制剂耐药的患者 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| CN119384281A (zh) | 2022-04-15 | 2025-01-28 | 深圳艾欣达伟医药科技有限公司 | 使用th-302单药或联用parp抑制剂治疗癌症的方法 |
| CN119233822A (zh) | 2022-05-23 | 2024-12-31 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| CN119894521A (zh) | 2022-09-22 | 2025-04-25 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| KR20250160163A (ko) | 2023-02-27 | 2025-11-11 | 아센타위츠 파마슈티컬즈 리미티드 | 용액, 동결건조 제형, 동결건조 제형 단위 패키지, 주사제, 및 주사제 제조 방법 |
| WO2025026214A1 (zh) | 2023-07-28 | 2025-02-06 | 深圳艾欣达伟医药科技有限公司 | 治疗p53基因突变或缺陷阴性癌症、肿瘤患者 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| CA2130578A1 (en) | 1992-04-17 | 1993-10-28 | Geewananda P. Gunawardana | Taxol derivatives |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| GB9909612D0 (en) | 1999-04-26 | 1999-06-23 | Cancer Res Campaign Tech | N-protected amines and their use as prodrugs |
| NZ521851A (en) | 2002-10-08 | 2005-02-25 | Auckland Uniservices Ltd | Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| AU2004285831B2 (en) | 2003-10-31 | 2011-09-15 | Auckland Uniservices Limited | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents |
| EP1896040B1 (en) | 2005-06-29 | 2012-08-01 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
| CA2624707A1 (en) | 2005-10-03 | 2007-04-12 | Genetix Pharmaceuticals, Inc. | Method for selectively depleting hypoxic cells |
| ES2884044T3 (es) | 2006-12-26 | 2021-12-10 | Immunogenesis Inc | Profármaco alquilante de fosforamidato para el tratamiento del cáncer |
| EP2350664B1 (en) * | 2008-10-21 | 2021-05-19 | ImmunoGenesis, Inc. | Treatment of cancer using the hypoxia activated prodrug th-302 in combination with docetaxel or pemetrexed |
| MX347225B (es) * | 2010-06-04 | 2017-04-19 | Abraxis Bioscience Llc * | Metodos de tratamiento contra el cancer pancreatico. |
| US20130296273A1 (en) | 2010-06-28 | 2013-11-07 | Threshold Pharmaceuticals, Inc. | Treatment of blood cancer |
| ES2877629T3 (es) | 2010-07-12 | 2021-11-17 | Immunogenesis Inc | Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer |
| WO2012135757A2 (en) * | 2011-04-01 | 2012-10-04 | Threshold Pharmaceuticals, Inc. | Methods for treating cancer |
| RU2013147744A (ru) | 2011-04-15 | 2015-05-20 | Тресхолд Фармасьютикалз, Инк. | Дозированная лекарственная форма для перорального применения |
| EP2793882A4 (en) | 2011-12-22 | 2015-04-29 | Threshold Pharmaceuticals Inc | ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER |
| EP2793899A4 (en) | 2011-12-22 | 2015-06-17 | Threshold Pharmaceuticals Inc | HYPOXIA-ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR CANCER TREATMENT |
| ES2909741T3 (es) | 2012-02-21 | 2022-05-10 | Immunogenesis Inc | Tratamiento del cáncer |
-
2014
- 2014-07-23 JP JP2016529868A patent/JP2016528217A/ja active Pending
- 2014-07-23 CN CN201480053041.5A patent/CN105792845A/zh active Pending
- 2014-07-23 EP EP14748448.9A patent/EP3024490A1/en not_active Withdrawn
- 2014-07-23 US US14/907,190 patent/US20160158253A1/en not_active Abandoned
- 2014-07-23 WO PCT/US2014/047885 patent/WO2015013448A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528217A5 (https=) | ||
| IL254377B (en) | Selective akr1c3 reductase activated prodrugs and their use for treating cancer patients | |
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| BR112018010671A8 (pt) | dispositivos e métodos de distribuição de fármaco com mudança de forma | |
| HK1216853A1 (zh) | 治療胰腺癌的方法 | |
| HUE055873T2 (hu) | Arany klaszter (AuCs) vagy AuCs-t tartalmazó anyagok alkalmazása glaukóma megelõzésére és/vagy kezelésére szolgáló gyógyszer elõállítására | |
| JP2014141525A5 (https=) | ||
| MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
| HK1255141A1 (zh) | 包含抗folr1免疫缀合物的治疗组合 | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| IL285440A (en) | Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| JP2017527582A5 (https=) | ||
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| HUE044317T2 (hu) | Szubsztituált 2-tioxo-imidazolin-4-on vegyületek és spiro-analógjaik, rákellenes alkotórész, gyógyászati készítmény, orvosi preparátum, eljárás prosztatarák kezelésére | |
| JP2018522028A5 (https=) | ||
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| HUE063047T2 (hu) | Rákellenes gyógyszerkészítmények kombinált terápiához | |
| IL267775A (en) | Combined treatment with a Lantrin-1 interfering drug and immune checkpoint inhibitor drugs | |
| HUE066216T2 (hu) | Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésében | |
| MX2022000394A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| CY1123539T1 (el) | Παραγων κατα των ογκων που περιλαμβανει ενυδρη υδροχλωρικη ιρινοτεκανη | |
| MA43178A (fr) | Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci | |
| EP3365026A4 (en) | ANTICIPATING AND INFLAMMATORY THERAPEUTICS AND METHOD THEREFOR | |
| HUE047272T2 (hu) | Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére |